Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.49 |
| ▸ | PPARA | Q07869 | 7/20 | 0.49 |
| ▸ | ACE | P12821 | 4/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5802884 | 1.00 | PPARG (0.49) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5802875 | 1.00 | PPARG (0.49) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5807048 | 0.96 | PPARG (0.47) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5807052 | 0.96 | PPARG (0.47) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5807051 | 0.96 | PPARG (0.47) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5803489 | 0.95 | PPARA (0.47) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5803490 | 0.95 | PPARA (0.47) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5803491 | 0.95 | PPARA (0.47) | PPARGPPARAACEMAPK14ICMT | |
| SCHEMBL5805956 | 0.92 | PPARG (0.48) | PPARGPPARAACEPPARDMEN1 | |
| SCHEMBL5805960 | 0.92 | PPARG (0.48) | PPARGPPARAACEPPARDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006083266-A1 | INHIBITORS OF BACTERIAL TYPE III PROTEIN SECRETION SYSTEMS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-08-10 | — | — | WO | disclosed |
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250819-A1 | Inhibitors of bacterial type III protein secretion systems | PSMB3, GBA3, PSMG3 | PPARG 4386/4885PPARA 4474/4885ACE 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.